24.6 C
New York
Sunday, June 14, 2026

Tag: manufacturing facility

Worksport Reports Consecutive Months of Record-Breaking Revenues, Gross Margin Improves by 25%

Company Reports All-Time-High Revenue in May 2025 (Following Record April 2025 Sales) as Gross Margins Rise 25% from Q1 2025 Levels; Growth Momentum Expected to Continue

Tigé Boats, Inc. Debuts Fully Redesigned Z3 for 2026

ABILENE, Texas, June 20, 2025 /PRNewswire/ -- Tigé Boats, Inc. is proud to release the all-new 2026 Z3. Representing the third generation of Tigé's...

LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma

Expanding track record by signing contracts with various global companies across Asia and EuropeSEOUL, South Korea, June 18, 2025 /PRNewswire/ -- LOTTE BIOLOGICS announced...

Methanol Market Size (9.1% CAGR) Forecasts to $64.14 Billion, Globally, by 2030 – Exclusive Study by The Research Insights

CHICAGO, June 18, 2025 /PRNewswire/ -- The Methanol Market size is projected to be valued at USD 41.55 billion in 2025 and reach USD 64.14 billion by 2030, growing at...

GlassPoint and Searles Valley Minerals Partner to Reduce Costs and Boost US Mineral Competitiveness

The project will deploy 750 MWth of GlassPoint's advanced solar technology to begin decommissioning two coal-fired power plants in California and strengthen domestic supply...

Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer OSLO, Norway, June...

Llusern Scientific Announces ISO 13485 Certification for its Point-of-Care Diagnostics System for Urinary Tract Infections

CARDIFF, United Kingdom, June 17, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a point-of-care diagnostics company, announces it has been awarded ISO 13485 certification for its Lodestar DX testing system, a rapid molecular diagnostic platform for urinary tract infections (UTIs). With industry-leading accuracy and speed, Lodestar DX empowers clinicians to diagnose and rule-out infections with precision in a single visit, thereby improving patient outcomes.

U.S. Food and Drug Administration Approves CSL’s ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacksOnce-monthly dosing reduced HAE attacks by a...

T1 Energy Advances $850 Million Planned 5 GW Solar Cell Plant

T1 Energy announces significant progress towards $850 million, 5 GW solar cell facility.

STL expands Data Centre portfolio to meet emerging requirements for AI data centres

- High-performance, comprehensive cabling and connectivity solutions and engineering services - Fully compliant solutions, meeting international standards MUMBAI, India, June 16, 2025 /PRNewswire/ -- STL (NSE:...

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

ITG Brands Celebrates 10-Year Anniversary with Charitable Giving and Continued Commitment to Jobs, Communities, and Economic Growth Across the U.S. and Caribbean

GREENSBORO, N.C., June 13, 2025 /PRNewswire/ -- ITG Brands, the third-largest company in its sector in the United States, is proudly celebrating its 10-year...

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsManufacturing facility